共 50 条
Dietary restriction for prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary angiography: a randomized controlled trial
被引:0
|作者:
Franziska Grundmann
Roman-Ulrich Müller
Karla Johanna Ruth Hoyer-Allo
Martin Richard Späth
Eva Passmann
Ingrid Becker
Roman Pfister
Stephan Baldus
Thomas Benzing
Volker Burst
机构:
[1] Department II of Internal Medicine and Center for Molecular Medicine Cologne,
[2] University of Cologne,undefined
[3] Faculty of Medicine and University Hospital Cologne,undefined
[4] CECAD,undefined
[5] University of Cologne,undefined
[6] Faculty of Medicine and University Hospital Cologne,undefined
[7] Institute of Medical Statistics and Computational Biology,undefined
[8] University of Cologne,undefined
[9] Department III of Internal Medicine,undefined
[10] Heart Center,undefined
[11] University Hospital of Cologne,undefined
[12] Systems Biology of Ageing Cologne,undefined
[13] University of Cologne,undefined
来源:
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Short-term dietary restriction (DR) may prevent organ damage from ischemic or toxic insults in animals, but clear evidence in humans is missing. While especially intraarterial administration of contrast media represents a cause of hospital-acquired acute kidney injury (AKI), targeted preventive strategies are not available. This trial investigated the feasibility and effectiveness of pre-interventional DR for preventing AKI in patients undergoing percutaneous coronary intervention (PCI). Patients were randomized to receive a formula diet containing 60% of daily energy requirement (DR group) or ad-libitum food during the 4-day-interval before PCI. Primary endpoint was change of serum creatinine 48 h after PCI (Δcreatinine). Further analyses included incidence of AKI and safety evaluation. Δcreatinine post PCI in the DR group vs. the control group did not show any difference (DR: 0.03(−0.15,0.14)mg/dL vs. control: 0.09(−0.03,0.22)mg/dL;p = 0.797). Subgroup analyses revealed a significant beneficial impact of DR in patients that received ≤100 ml of contrast agent (DR n = 26: Δcreatinine −0.03(−0.20,0.08)mg/dL vs. control n = 24: Δcreatinine 0.10(−0.08,0.24)mg/dL; p = 0.041) and in patients with ≤2 risk factors for AKI (DR: n = 27; Δcreatinine −0.01(−0.18,0.07)mg/dL vs. control n = 31: Δcreatinine 0.09(−0.03,0.16)mg/dl; p = 0.030). Although the primary endpoint was not met, the results of this trial suggest a beneficial impact of DR in low-to-moderate risk patients.
引用
收藏
相关论文